MyFinsight
Home
Blog
About
Contact
Download
Download image
Sales and maturities
of marketable...
$52,261K
Proceeds from issuance of
common stock
$22,276K
Proceeds from shares
issued under espp
$36K
Net cash provided by
investing activities
$25,556K
Net cash provided by
financing activities
$22,312K
Canceled cashflow
$26,705K
Net increase
(decrease) in cash and cash...
-$1,745K
Canceled cashflow
$47,868K
Accrued liabilities and
other liabilities
-$4,334K
Stock-based compensation
$2,986K
Depreciation and
amortization
$2,185K
Prepaid expenses and
other assets
-$1,102K
Noncash operating lease
expense
$587K
Purchases of marketable
securities
$26,705K
Net cash used in
operating activities
-$49,613K
Canceled cashflow
$11,194K
Net loss
-$55,844K
Accounts payable
-$3,342K
Lease liabilities
-$1,005K
Amortization of premiums and
discounts on marketable...
$481K
Other long-term
liabilities
-$135K
Back
Back
Cash Flow
source: myfinsight.com
NextCure, Inc. (NXTC)
NextCure, Inc. (NXTC)